Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14
Published . Updated .
The average one-year price target for Capricor Therapeutics (NASDAQGS:CAPR) (DB:4LN2) has been revised to $24.14 / share. This is an increase of 12.70% from the prior estimate of $21.42 dated September 11, 2026. These figures represent aggregate analyst targets compiled from vari
Directly affected
- CAPR Capricor Therapeutics
Named in this report.
Indirectly affected
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Capricor Therapeutics (NASDAQGS:CAPR) (DB:4LN2) has been revised to $24.14 / share. This is an increase of 12.70% from the prior estimate of $21.42 dated September 11, 2026. These figures represent agg…
Source: Nasdaq Markets
The price since 2 Oct 2026: Capricor Therapeutics (CAPR) versus the S&P 500
Since the first closing price after “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14,” Capricor Therapeutics (CAPR) is -14.52%. The S&P 500 fund (SPY) is -1.08% over the same days, a -13.44% difference versus the market.
Who gains and who loses around Capricor Therapeutics (CAPR)
Companies carried with this story
- CAPR Capricor Therapeutics
In “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14,” Capricor Therapeutics (CAPR) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names CAPRICOR THERAPEUTICS INC in the headline; GA resolved that company to CAPR
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
In “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14,” Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence. Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
In “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
In “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14,” Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence. Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14.” Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
In “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14,” Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
In “Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14,” Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Capricor Therapeutics (CAPR)
“Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14” (2 Oct 2026) reaches Capricor Therapeutics (CAPR) through this story.
What ties Capricor Therapeutics (CAPR) to the headline is this: The reported development directly names CAPRICOR THERAPEUTICS INC in the headline; GA resolved that company to CAPR
Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is here too. Its reason reads: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Capricor Therapeutics (CAPR), and the dates in the story
BTCZ traded between 2.69 and 3.21 across 20 sessions. The latest close on file is 3.06. CAPR traded between 6.47 and 10.72 across 20 sessions. The latest close on file is 6.65. DOGG traded between 20.68 and 22.21 across 20 sessions. The latest close on file is 21.99.
A simple score for Capricor Therapeutics (CAPR)
46 out of 100
“Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.